Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The aims of this study were to determine whether there is a cross-sectional relationship between urinary albumin excretion rate and cardiovascular disease in nondiabetic subjects and to investigate hereditary predisposition to microalbuminuria by studying offspring of the main study population.
|
8086657 |
1994 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Adverse reactions to human serum albumin.
|
8431628 |
1993 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The differences in lipoproteins we describe for the identical twins discordant for insulin-dependent diabetes mellitus, in whom there was no evidence of a raised urinary albumin excretion rate, does not appear to explain the excess mortality from cardiovascular disease reported in patients with this disease.
|
8504630 |
1993 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study the prevalence of cardiovascular disease mortality and morbidity and of risk factors for cardiovascular disease was compared in the parents of 31 IDDM patients with elevated albumin excretion rate (AER > 45 microg/min; group A) with that of parents of 31 insulin-dependent diabetic patients with normoalbuminuria (AER < 20 microg/min; group B).
|
9349601 |
1997 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Urinary albumin excretion is associated with cardiovascular disease outcomes and risk factors among American Indians of the Great Lakes region.
|
9767548 |
1998 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, the association between the RAGE -374 T/A homozygous AA genotype and cardiovascular disease as well as albumin excretion in type 1 diabetic patients with poor metabolic control suggests a gene-environment interaction in the development of diabetic nephropathy and cardiovascular complications.
|
12606536 |
2003 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In a cohort of 258 (161 males) ESRD patients starting renal replacement therapy [glomerular filtration rate (GFR) 6.8 +/- 0.2 mL/min] aged 52 +/- 1 years the following parameters were studied: presence of malnutrition (subjective global assessment), comorbidity [diabetes mellitus and clinical manifest cardiovascular disease (CVD)], carotid plaques (N= 101), hs-CRP, fetuin-A, S-albumin, interleukin (IL)-6, and single nucleotide polymorphisms (SNPs) in the AHSG gene (N= 215) at amino acid positions Thr248Met (C-->T), Thr256Ser (C-->G), Asp276Asn (G-->A), and Arg317Cys (C-->T).
|
15882283 |
2005 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The dyslipidemia of insulin resistance, with high levels of albumin-bound fatty acids, is a strong cardiovascular disease risk.
|
16239593 |
2006 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Age, cardiovascular disease and serum albumin were found to be independent predictors of patient survival.
|
16244470 |
2005 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Data were collected on HbA(1c), blood pressure, urinary albumin excretion rate, kidney function, retinopathy, smoking, medication and cardiovascular disease.
|
17704113 |
2008 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Chronic kidney disease (CKD) phenotypes such as albuminuria measured by urinary albumin creatinine ratio (ACR), elevated serum creatinine (SrCr) and/or decreased creatinine clearance (CrCl) and glomerular filtration rate (eGFR) are major risk factors for renal and cardiovascular diseases.
|
18443212 |
2008 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our finding suggests another added benefit of statins' treatments in preventing CVD through stimulation of HSA biosynthesis.
|
19291315 |
2009 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Damage to the filtration barrier results in albumin loss in the urine, a hallmark of cardiovascular disease and kidney failure.
|
24231357 |
2013 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No correlations were found between serum ACE concentration (or genotype) and cardiovascular diseases, in accordance with the proposed suppressed physiological ACE activities by HSA (concentration in the sera of these patients: 48.5 ± 0.5 mg/mL) or other endogenous inhibitors.
|
24690767 |
2014 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
A full biochemical profile for cardiovascular disease risk assessment includes a lipid profile, glucose, glycated haemoglobin and urine albumin creatinine ratio measurements.
|
27422136 |
2017 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In COPD patients, RDW levels positively correlated with CRP levels (r=0.27, P<.001), albumin levels (r=0.23, P=.04), right ventricular dysfunction (RVD) (r=0.24, P=.001), pulmonary hypertension (PAH) (r=0.1, P=.02), and presence of CVD (r=0.24, P=.02).
|
27670684 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
After adjusting gender, age, baseline serum creatinine (SCr), body mass index (BMI), serum albumin (ALB), alanine aminotransferase (ALT), hemoglobin, white blood cell count (WBC), triglyceride (TG), total cholesterol (TC), hypertension, cardiovascular disease (CVD), diabetes, smoking and drinking status, the risk for CKD increased with the elevated serum GGT quartiles.
|
27704320 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
However, for patients with protein-creatinine ratio >500 mg/g (albumin-creatinine ratio > 300 mg/g), with or without diabetes, lower SBP target should be proposed for renal protection aiming SBP < 130 mmHg as recommended by KDIGO guidelines.In patients at low or intermediate risk, without cardiovascular disease, SBP should start to be treated when SBP is above 140 mmHg, and when treated, target BP should be less than 140 mmHg as reported by HOPE-3 trial.
|
27722961 |
2017 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In multivariable analyses, plasma sRAGE (hazard ratio [HR] = 1.155; 95% confidence interval [CI] = 0.612-2.183; P = 0.656) and S100A12 (HR = 0.960; 95% CI = 0.566-1.630; P = 0.881) were not associated with mortality in HD patients, although traditional predictors of mortality, including age, history of cardiovascular diseases (CVDs), and serum levels of albumin and hsCRP were related to mortality.
|
27914132 |
2017 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
After adjustments for cardiovascular disease risk factors, donor type, dialysis vintage, serum albumin and allograft function, only increased PTH and FePi remained associated with the outcome.
|
27981393 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Risk of mortality was evaluated using a Cox proportional hazard regression model adjusted for sex, age, hypertension, diabetes mellitus, CKD stage, serum albumin, high-density lipoprotein cholesterol, uric acid, hemoglobin, body mass index, glutamic-pyruvic transaminase, smoking, alcohol consumption, and history of cardiovascular disease (coronary artery disease, congestive heart failure, cerebral vascular disease), history of cancer, and history of chronic obstructive pulmonary disease.
|
28045962 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
We evaluated if the associations of urine albumin creatinine ratio (ACR) with all-cause and CVD mortality differed depending on serum concentrations of persistent organic pollutants (POPs), strong lipophilic chemical mixtures with very long half-lives, which are recently linked to many degenerative diseases.
|
28226276 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The factors included age, gender, diabetes mellitus (DM), body mass index (BMI), previous cardiovascular disease (CVD), HD duration, hemoglobin, albumin, white blood cell, C-reactive protein (CRP), parathyroid hormone, total iron binding capacity (TIBC), iron, ln ferritin, adiponectin, apolipoprotein A1 (ApoA1), ApoA2, ApoA3, high-density lipoprotein (HDL), total cholesterol, hemoglobin A1c (HbA1c), serum phosphate, troponin T (TnT), and B-type natriuretic peptide (BNP).
|
28341375 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Based on area under the receiver operating characteristic curve (AUC) analysis, RDW (AUC = 0.699) had a stronger predictive value for all-cause and CVD-related mortality than other biological markers including hemoglobin (AUC = 0.51), ferritin (AUC = 0.584), iron saturation (AUC = 0.535), albumin (AUC = 0.683) and white blood cell count (AUC = 0.588).
|
28367961 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Urinary albumin might be more attributable to CVD and all-cause mortality than HTN.
|
28472229 |
2017 |